[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Adma Biologics (ADMA)

Adma Biologics (ADMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,017,207
  • Shares Outstanding, K 238,159
  • Annual Sales, $ 510,170 K
  • Annual Income, $ 146,930 K
  • EBIT $ 192 M
  • EBITDA $ 200 M
  • 60-Month Beta 0.83
  • Price/Sales 4.71
  • Price/Cash Flow 15.41
  • Price/Book 5.02

Options Overview Details

View History
  • Implied Volatility 66.27% (+2.72%)
  • Historical Volatility 70.52%
  • IV Percentile 61%
  • IV Rank 24.78%
  • IV High 147.60% on 03/27/26
  • IV Low 39.48% on 01/22/26
  • Expected Move (DTE 7) 0.68 (8.32%)
  • Put/Call Vol Ratio 1.01
  • Today's Volume 3,458
  • Volume Avg (30-Day) 3,891
  • Put/Call OI Ratio 0.35
  • Today's Open Interest 143,264
  • Open Int (30-Day) 145,299
  • Expected Range 7.49 to 8.85

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $0.15
  • Growth Rate Est. (year over year) +665,900.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.50 +8.93%
on 05/07/26
11.42 -28.46%
on 04/24/26
-1.66 (-16.89%)
since 04/08/26
3-Month
7.21 +13.31%
on 03/26/26
17.16 -52.39%
on 03/02/26
-8.26 (-50.27%)
since 02/06/26
52-Week
7.21 +13.31%
on 03/26/26
22.37 -63.48%
on 06/11/25
-13.03 (-61.46%)
since 05/08/25

Most Recent Stories

More News
Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA

NEW YORK , May 8, 2026 /PRNewswire/ --

ADMA : 8.17 (-3.54%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA

NEW YORK , May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA).  Such investors are advised...

ADMA : 8.17 (-3.54%)
Adma Biologics: Q1 Earnings Snapshot

Adma Biologics: Q1 Earnings Snapshot

ADMA : 8.17 (-3.54%)
ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update

1Q 2026 Total Revenue of $114.5 Million, Flat Year-Over-Year  1Q 2026 ASCENIV Revenue +28% Year-Over-Year; BIVIGAM Revenue -54% Year-Over-Year 1Q 2026 Adjusted Net Income ( 1) of $40.7...

ADMA : 8.17 (-3.54%)
ADMA Biologics Reports Tuesday but the Channel Stuffing Allegations Haven't Gone Away

Barchart Research What to Expect from ADMA Earnings ADMA Generated May 5, 2026 Current Price $10.25 Consensus Rating Moderate Buy Average Move 14.00% ADMA Biologics Reports Tuesday but the Channel Stuffing...

ADMA : 8.17 (-3.54%)
ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age and Older

RAMSEY, N.J. and BOCA RATON, Fla., May 04, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company...

ADMA : 8.17 (-3.54%)
Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA

NEW YORK , May 1, 2026 /PRNewswire/ --

ADMA : 8.17 (-3.54%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA

NEW YORK , April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors are advised...

ADMA : 8.17 (-3.54%)
ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026

RAMSEY, N.J. and BOCA RATON, Fla., April 29, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company...

ADMA : 8.17 (-3.54%)
Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA

NEW YORK , April 25, 2026 /PRNewswire/ --

ADMA : 8.17 (-3.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is below 30%. The market is in oversold territory. Watch for a potential trend reversal.

See More Share

Business Summary

ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company's target patient populations include immune-compromised individuals who suffer from an underlying...

See More

Key Turning Points

3rd Resistance Point 9.63
2nd Resistance Point 9.27
1st Resistance Point 8.72
Last Price 8.17
1st Support Level 7.82
2nd Support Level 7.46
3rd Support Level 6.91

See More

52-Week High 22.37
Fibonacci 61.8% 16.58
Fibonacci 50% 14.79
Fibonacci 38.2% 13.00
Last Price 8.17
52-Week Low 7.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.